Big pharma, Partnering

Forest in settlement agreement for Bystolic with Glenmark Generics

Posted on 14 February 2013

Tags: , ,

Forest Laboratories  entered into settlement agreement with a company that wanted marketing approval for a generic version of its blood pressure drug Bystolic.

The patent infringement suit was against Glenmark Generics Inc.

Under the settlement agreement, Glenmark will be able to start selling a lower-cost version of Bystolic about three months before the patents protecting the drug expire.

The drug is a member of the beta blocker family of medications that control high blood pressure by relaxing blood vessels and slowing heart rate.

Earlier this year Forest and Johnson & Johnson sued Glenmark and several other drugmakers.

Most of the lawsuits have been settled, but suits against Watson Pharmaceuticals Inc. and Amerigen Pharmaceuticals Ltd. have not been resolved.

Forest got about one-sixth of its total revenue from Bystolic in its latest fiscal quarter.

The company is also studying a drug that combines Bystolic with valsartan, an older blood pressure drug sold under the name Diovan.

For further deal information visit Current Agreements (subscription required)

Related

Report: Cardiovascular Partnering Terms and Agreements

Report: Partnering Deals and Alliances with Forest Laboratories

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Print Friendly, PDF & Email

Leave a Reply